Following a resubmission to the Scottish Medicnes Consortium (SMC), zanubrutinib has now been approved for use within NHS Scotland. This a great result for the WM community in Scotland and gives patients a wider choice of treatment options.
Jane Nicholson, CEO at WMUK said:
"Following a disappointing decision by the SMC earlier this year, we are really thrilled that the resubmission has been approved and that zanubrutinib is now also going to be a treatment option for the Scottish WM community.
We'd like to thank everyone involved in helping inform this decision and to everyone that took their time to be involved in the process. Your ongoing support means that WM patients in Scotland have more options when it comes to treating WM. We're also pleased to have been able to contribute to the consultation process and ensuring the patient voice is heard."
More information Note: This advice applies only in the context of an approved NHS Scotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower. This advice also took into account of the views from a Patient and Clinician Engagement (PACE) meeting.